Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer

作者：Xiaohua Wu, Lingfang Xia, Keqiang Zhang, Ying Tang, Guonan Zhang, Danbo Wang, Hanmei Lou, Naifu Liu, Hongping Zhang, Hongwei Chen, Ke Wang, Shuqing Wei, Li Wang, Kun Gao, Guiling Li, Huifeng Zhang, Yuanjing Hu, Xianfeng Zhou, Yuting Wang, Quanren Wang · 发表于：Gynecologic Oncology · 年份：2024 · DOI：10.1016/j.ygyno.2024.07.040 · 被引用次数：3 · 研究领域：Endometrial and Cervical Cancer Treatments、Gastric Cancer Management and Outcomes、Cancer Immunotherapy and Biomarkers